Ovarian Cancer Clinical Trials in New York

Showing 21-40 of 134 trials

A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer

NCT06394804

The researchers are doing this study to find out whether the combination of avutometinib, defactinib, and letrozole is an effective treatment for people with low-grade serous ovarian cancer (LGSOC). The researchers will also look at the safety of this combination.

Low-Grade Serous Ovarian Cancer

Memorial Sloan Kettering Cancer Center20 participantsStarted Apr 2024

Atlanta, Georgia, United States • Basking Ridge, New Jersey, United States • Middletown, New Jersey, United States +5 more locations

RECRUITINGPHASE2< 1 mile

Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery

NCT06290193

Participants will be scheduled for primary cytoreductive surgery as part of their standard care. Before surgery, participants will be assigned by chance to a study group. Depending on which group they are in, they will receive either acute normovolemic hemodilution/ANH during surgery or standard surgical management during surgery. The researchers think acute normovolemic hemodilution/ANH may decrease the need for allogenic blood transfusion/ABT in people having primary cytoreductive surgery.

Ovarian CancerFallopian Tube CarcinomaOvarian Carcinoma+7 more

Memorial Sloan Kettering Cancer Center86 participantsStarted Feb 2024

Basking Ridge, New Jersey, United States • Middletown, New Jersey, United States • Montvale, New Jersey, United States +4 more locations

A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer

Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery

Ovarian Cancer Trials in Other Cities

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Study of AVZO-021 in Patients With Advanced Solid Tumors

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

A Study of XMT-1660 in Participants With Solid Tumors

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

EXoPERT EMERALD Clinical Study

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Other Conditions in New York